WELLS FARGO & COMPANY/MN - NYMOX PHARMACEUTICAL CORP ownership

NYMOX PHARMACEUTICAL CORP's ticker is NYMX and the CUSIP is P73398102. A total of 5 filers reported holding NYMOX PHARMACEUTICAL CORP in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of NYMOX PHARMACEUTICAL CORP
ValueSharesWeighting
Q2 2023$627
-44.1%
3,2960.0%0.00%
Q1 2023$1,121
+12.0%
3,296
+6.5%
0.00%
Q4 2022$1,001
-83.3%
3,096
-78.6%
0.00%
Q3 2022$6,000
-40.0%
14,493
+93.8%
0.00%
Q4 2021$10,000
-33.3%
7,4780.0%0.00%
Q3 2021$15,000
+25.0%
7,4780.0%0.00%
Q2 2021$12,000
-97.6%
7,478
-96.7%
0.00%
Q1 2021$506,000
+462.2%
227,589
+533.6%
0.00%
Q4 2020$90,000
+47.5%
35,920
+45.2%
0.00%
Q3 2020$61,000
-19.7%
24,745
+14.7%
0.00%
Q2 2020$76,000
+1800.0%
21,568
+846.4%
0.00%
Q2 2019$4,000
-85.7%
2,279
-84.2%
0.00%
Q1 2019$28,000
+47.4%
14,443
-0.0%
0.00%
Q4 2018$19,000
-54.8%
14,447
-15.1%
0.00%
Q3 2018$42,000
-50.0%
17,014
-32.4%
0.00%
Q2 2018$84,000
+37.7%
25,183
+73.7%
0.00%
Q1 2018$61,000
+103.3%
14,496
+55.8%
0.00%
Q4 2017$30,000
+150.0%
9,303
+192.6%
0.00%
Q3 2017$12,000
+200.0%
3,179
+202.8%
0.00%
Q2 2017$4,000
+33.3%
1,0500.0%0.00%
Q1 2017$3,0000.0%1,0500.0%0.00%
Q4 2016$3,0000.0%1,0500.0%0.00%
Q3 2016$3,000
-76.9%
1,050
-74.1%
0.00%
Q2 2016$13,000
+30.0%
4,0500.0%0.00%
Q1 2016$10,000
-23.1%
4,0500.0%0.00%
Q4 2015$13,0004,0500.00%
Other shareholders
NYMOX PHARMACEUTICAL CORP shareholders Q3 2023
NameSharesValueWeighting ↓
First Citizens Financial Corp 35,100$89,0000.08%
Geier Asset Management, Inc. 35,000$91,0000.07%
Patriot Financial Group Insurance Agency, LLC 43,250$107,0000.03%
Willow Creek Wealth Management Inc. 24,224$60,0000.02%
WEBSTER BANK, N. A. 70,000$174,0000.02%
Brown Advisory Securities, LLC 28,000$69,0000.01%
Cubic Asset Management, LLC 11,250$28,0000.01%
Tower Research Capital LLC (TRC) 25,613$64,0000.00%
GOFEN & GLOSSBERG LLC /IL/ 25,000$62,0000.00%
Sterling Investment Advisors, Ltd. 2,500$6,0000.00%
View complete list of NYMOX PHARMACEUTICAL CORP shareholders